Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $166.7M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts SYRS Hot Sheet
Join SI Premium – FREE
Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.41), $0.03 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $4.49 million.
For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Celanese Corp. (CE) Tops Q3 EPS by 9c; offers guidance
- Voya Financial (VOYA) Reports In-Line Q3 EPS
- Allison Transmission (ALSN) Tops Q3 EPS by 58c; raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
